Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein

• 成果类型: Article
• 署名作者: Radic, Laura; Offersgaard, Anna; Kadava, Tereza; Zon, Ian; Capella-Pujol, Joan; Mulder, Fabian; Koekkoek, Sylvie; Spek, Vera; Chumbe, Ana; Bukh, Jens; van Gils, Marit J.; Sanders, Rogier W.; Yin, Victor C.; Heck, Albert J. R.; Gottwein, Judith M.; Sliepen, Kwinten; Schinkel, Janke
• 署名单位: University of Amsterdam; University of Copenhagen; University of Copenhagen; Utrecht University; Utrecht University; Cornell University; Weill Cornell Medicine
• 刊物名称: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
• ISSN/ISSBN: 0027-11273
• DOI: 10.1073/pnas.2420402122
• 发表日期: 2025-04-15
• 关键词: broadly neutralizing antibodies; human monoclonal-antibodies; infection; vaccine; clearance; breadth; replication; resistance; FUTURE; ap33

摘要

Hepatitis C virus (HCV) currently causes about one million infections and 240,000 deaths worldwide each year. To reach the goal set by the World Health Organization of global HCV elimination by 2030, it is critical to develop a prophylactic vaccine. Broadly neutralizing antibodies (bNAbs) target the E1E2 envelope glycoproteins on the viral surface, can neutralize a broad range of the highly diverse circulating HCV strains, and are essential tools to inform vaccine design. However, bNAbs targeting a single E1E2 epitope might be limited in neutralization breadth, which can be enhanced by using combinations of bNAbs that target different envelope epitopes. We have generated 60 immunoglobulin G (IgG)-like bispecific antibodies (bsAbs) that can simultaneously target two distinct epitopes on E1E2. We combine non-or partially overlapping E1E2 specificities into three types of bsAbs, each containing a different hinge length. The majority of bsAbs shows retained or increased potency and breadth against a diverse panel of HCV pseudoparticles and HCV produced in cell culture compared to mono-specific and cocktail controls. Additionally, we demonstrate that changes in the hinge length of bsAbs can alter the binding stoichiometry to E1E2. These results provide insights into the binding modes and the role of avidity in bivalent targeting of diverse E1E2 epitopes.This study illustrates how potential cooperative effects of HCV bNAbs can be utilized by strategically designing bispecific constructs. These HCV bsAbs can guide vaccine development and unlock novel therapeutic and prophylactic strategies against HCV and other (flavi)viruses.